These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 1816768)
21. Cytotoxic activity of cyclosporin A and [3-keto-Bmt1]-[Val2]-cyclosporin (SDZ PSC 833) on tumour cells from patients with haematological malignancies. Martinsson P; Nygren P; Fridborg H; Nilsson K; Kristensen J; Larsson R Eur J Clin Pharmacol; 1997; 52(3):199-203. PubMed ID: 9218926 [TBL] [Abstract][Full Text] [Related]
22. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Watanabe T; Nakayama Y; Naito M; Oh-hara T; Itoh Y; Tsuruo T Anticancer Drugs; 1996 Nov; 7(8):825-32. PubMed ID: 8991185 [TBL] [Abstract][Full Text] [Related]
23. Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives. Gavériaux C; Boesch D; Boelsterli JJ; Bollinger P; Eberle MK; Hiestand P; Payne T; Traber R; Wenger R; Loor F Br J Cancer; 1989 Dec; 60(6):867-71. PubMed ID: 2481487 [TBL] [Abstract][Full Text] [Related]
24. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202 [TBL] [Abstract][Full Text] [Related]
25. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. Liminga G; Nygren P; Larsson R Exp Cell Res; 1994 Jun; 212(2):291-6. PubMed ID: 7910563 [TBL] [Abstract][Full Text] [Related]
26. Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins. Twentyman PR Br J Cancer; 1988 Mar; 57(3):254-8. PubMed ID: 2833299 [TBL] [Abstract][Full Text] [Related]
27. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers. Pilarski LM; Yatscoff RW; Murphy GF; Belch AR Leukemia; 1998 Apr; 12(4):505-9. PubMed ID: 9557608 [TBL] [Abstract][Full Text] [Related]
28. Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro. Twentyman PR; Wright KA; Wallace HM Br J Cancer; 1992 Mar; 65(3):335-40. PubMed ID: 1313690 [TBL] [Abstract][Full Text] [Related]
29. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein. Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401 [TBL] [Abstract][Full Text] [Related]
30. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Lucci A; Han TY; Liu YY; Giuliano AE; Cabot MC Cancer; 1999 Jul; 86(2):300-11. PubMed ID: 10421266 [TBL] [Abstract][Full Text] [Related]
31. Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein. Watanabe T; Kokubu N; Charnick SB; Naito M; Tsuruo T; Cohen D Br J Pharmacol; 1997 Sep; 122(2):241-8. PubMed ID: 9313931 [TBL] [Abstract][Full Text] [Related]
32. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. Jachez B; Nordmann R; Loor F J Natl Cancer Inst; 1993 Mar; 85(6):478-83. PubMed ID: 8095304 [TBL] [Abstract][Full Text] [Related]
33. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Archinal-Mattheis A; Rzepka RW; Watanabe T; Kokubu N; Itoh Y; Combates NJ; Bair KW; Cohen D Oncol Res; 1995; 7(12):603-10. PubMed ID: 8704277 [TBL] [Abstract][Full Text] [Related]
34. Derivation and characterisation of a mouse tumour cell line with acquired resistance to cyclosporin A. Wright KA; Twentyman PR Eur J Cancer; 1993; 29A(3):389-94. PubMed ID: 8104444 [TBL] [Abstract][Full Text] [Related]
35. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Colombo T; Gonzalez Paz O; D'Incalci M Br J Cancer; 1996 Apr; 73(7):866-71. PubMed ID: 8611397 [TBL] [Abstract][Full Text] [Related]
36. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Speeg KV; Maldonado AL Cancer Chemother Pharmacol; 1994; 34(2):133-6. PubMed ID: 7910787 [TBL] [Abstract][Full Text] [Related]
37. The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. Cabot MC; Han TY; Giuliano AE FEBS Lett; 1998 Jul; 431(2):185-8. PubMed ID: 9708899 [TBL] [Abstract][Full Text] [Related]
38. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin. Michieli M; Damiani D; Michelutti A; Melli C; Ermacora A; Geromin A; Fanin R; Russo D; Baccarani M Haematologica; 1996; 81(4):295-301. PubMed ID: 8870372 [TBL] [Abstract][Full Text] [Related]
39. Combined use of tamoxifen, cyclosporin A, and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines. Kim JH; Chung JB; Park IS; Kim BS; Yoo NC; Choi JH; Roh JK; Kim HS; Kwon OH; Lee KS Yonsei Med J; 1993 Mar; 34(1):35-44. PubMed ID: 8397460 [TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]